Urology · 5-alpha reductase inhibitorRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Finasteride by Sun Pharma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 12:32:58 AM

Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Sun Pharma's supplemental application for Finasteride is a significant regulatory milestone that could enhance their competitive positioning in the urology market. Portfolio teams should closely monitor the review timeline and potential market implications. Regulatory context from FDA (FDA AP — FINASTERIDE (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of this supplement on Sun Pharma's market share and competitive strategy in urology. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Urology · 5-alpha reductase inhibitor, 4 regulatory and 6 competitive items passed relevance filtering for Sun Pharma.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This acceptance may enhance Sun Pharma's position in the market for treatments related to benign prostatic hyperplasia and androgenetic alopecia.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FINASTERIDE (SUPPL) (FDA). Entity match (finasteride); Regulatory pathway relevance (nda). The acceptance of this supplemental application indicates a pathway towards potential approval, which could affect compliance and labeling strategies for competitors in the market.

Key Risks

Elevated medium regulatory exposure for Sun Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this supplement could improve Sun Pharma's market share in urology, impacting revenue from treatments for benign prostatic hyperplasia and androgenetic alopecia.
Upside for Sun Pharma may improve if Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Sun Pharma may improve if A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Sun Pharma may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the potential impact of this supplement on Sun Pharma's market share and competitive strategy in urology.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for FDA review and any subsequent approvals or market launches.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (finasteride); Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA grants priority review for NUPLAZID supplemental application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for NUPLAZID Supplement NDA210793
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment

Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran.
PubMedhigh relevance
Entity match (finasteride)
FDA document
View source
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis of the landscape.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sun Pharma
Finasteride

Commercial impact

medium

If approved, this supplement could improve Sun Pharma's market share in urology, impacting revenue from treatments for benign prostatic hyperplasia and androgenetic alopecia.

Regulatory impact

medium

The acceptance of this supplemental application indicates a pathway towards potential approval, which could affect compliance and labeling strategies for competitors in the market.

What to watch

Monitor the timeline for FDA review and any subsequent approvals or market launches.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.